Economic Burden of Hidradenitis Suppurativa in Spain
Por:
Vilarrasa, E, Borrás-Blasco, J, Lobo-Benito, S, Loro-Pérez, M, Núñez-García, MG, Oliva-Moreno, J, Palacios-Martínez, D, Rubial-Bernárdez, F, Ivanova-Markova, Y, Daheron, M, Bellas, J, Martorell, A
Publicada:
1 mar 2026
Ahead of Print:
1 feb 2026
Resumen:
IntroductionHidradenitis suppurativa (HS) is a highly disabling chronic inflammatory disorder affecting up to 1% of the Spanish population. It is a complex disease that requires significant resources and imposes a considerable economic burden. The aim of this study was to assess the economic burden of diagnosed HS in Spain both at patient and population level.MethodsThe study was conducted from a societal perspective using a bottom-up, prevalence-based approach. We evaluated publicly financed direct healthcare costs (consultations, diagnostic tests, inpatient admissions, surgery, comorbidities, treatment), direct nonhealthcare costs (formal and informal care, out-of-pocket expenses), and indirect costs (absenteeism and productivity loss) incurred by patients diagnosed with HS. A sensitivity analysis was conducted to test the uncertainty of the model.ResultsThe mean annual cost of treating all severities of patients with HS in Spain was & euro;39,535.10. The largest cost components across all categories were informal care (46.05%), treatment (18.24%), out-of-pocket expenses (12.76%), loss of work productivity (10.82%), and surgery (5.62%). Moderate and severe patients cost 64.05% (& euro;34,221.92) and 170.53% (& euro;56,432.77) more than mild patients (& euro;20,860.35), respectively. Assuming a prevalence of 1% and a diagnostic rate of 10%, the total economic burden of diagnosed HS in Spain was estimated at & euro;1587 million.ConclusionsHS has a significant economic impact on patients, their families, the healthcare system, and wider society. This is particularly evident among patients with moderate-to-severe HS. To reduce the economic burden and improve quality of life, efforts should be made to prevent the disease from progressing and to ensure that patients remain in the milder stages.
Filiaciones:
Vilarrasa, E:
Hosp Santa Creu & Sant Pau, Dermatol, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Borrás-Blasco, J:
Hosp Sagunto, Farmacy, Valencia, Spain
Lobo-Benito, S:
Assoc Suppurat Hidrosadenitis Patients, Madrid, Spain
Loro-Pérez, M:
Univ Hosp Puerta Hierro, Psychol, Majadahonda, Spain
Núñez-García, MG:
Univ Hosp La Paz, Nursing, Madrid, Spain
Oliva-Moreno, J:
Univ Castilla La Mancha, Toledo, Spain
CIBERFES, Madrid, Spain
ISCIII, Madrid, Spain
IDISCAM, Toledo, Spain
Palacios-Martínez, D:
Spanish Soc Primary Care Phys, Madrid, Spain
Rubial-Bernárdez, F:
Marques De Valdecilla Univ Hosp, Santander, Spain
Ivanova-Markova, Y:
Weber, Madrid, Spain
Daheron, M:
Weber, Madrid, Spain
Bellas, J:
UCB, Madrid, Spain
Martorell, A:
Hosp Manises, Dermatol, Valencia, Spain
Green Submitted, gold
|